ABSTRACT The overall premise of this PPG application is that there are shared biologic pathways in the development of COPD and IPF. To further understand the epidemiologic, biologic, and genetic characteristics of COPD and IPF (divergent pulmonary response to common noxious exposures such as tobacco smoke) we are proposing to aggregate and curate data from several existing COPD and IPF cohorts as well as create a de-novo bron- choscopy cohort. This Clinical Biorepository Core will provide a harmonized standard dataset for all co- investigators in this application. These data will include clinical, epidemiologic, physiologic and radiologic sub- typing information as well as biospecimens which will be used for cross sectional and longitudinal analyses. To achieve these goals, the Clinical Biorepository Core has brought together an internationally recognized team of investigators whose expertise spans clinical investigation, radiologic assessments and bronchoscopic studies. The existing cohorts to be leveraged by this investigation include three NIH funded projects, COPDGene, SPIROMICS and the Lung Tissue Research Consortium (LTRC), each of which has a wealth of phenotypic data that will be leveraged for disease subtyping. This Core will also leverage a foundation funded effort called the Pulmonary Fibrosis Foundation Clinical Care Registry and Biorepository (PFF). Finally, the prospective Bronchoscopy Population will include 40 ex-smoking subjects with COPD (20 with emphysema predominant and 20 with airway predominant disease), 30 ex-smokers with IPF (15 with Typical UIP and 15 with probable/inconsistent UIP) and 20 age and sex matched controls (all ex-smokers).